Research news

The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its ‘Phase 3’ trials which involved UCLH that show its candidate vaccine is effective at preventing COVID-19 and offers a high level of protection.

Fears that people with high blood pressure are more at risk from severe Covid-19 because it is easier for the virus to enter their cells and tissues have been laid to rest, thanks to research involving UCLH.

Sir Simon Stevens, CEO of NHS England visited our long COVID-19 clinic today to learn more about the service at UCLH.

UCLH will be part of a first-of-its kind clinical trial, led by scientists at UCL, that will evaluate the use of ‘real time’ viral genomic data to reduce the spread of COVID-19 within hospitals.

Acute loss of sense of smell should be considered globally as a criterion for self-isolation, testing, and contact tracing for Covid-19 infection according to researchers at UCLH and UCL.